PROBLEM TO BE SOLVED: To provide a predetermined TNF- inhibitor which is used in a medicine composition for treating a myelopathy as a nerve root injury caused by the release of TNF-. SOLUTION: The TNF- inhibitor has a form of a base or addition salt thereof selected from the group consisting of metalloproteinase inhibitor excluding methylprenizolone tetracycline including chemically-modified tetracycline quinolone corticosteroid thalidomide lazaroid pentoxifylline hydroxamic acid derivatives c...

A talmy tgya cskentett mellhat elsorban a sz erejfokozgyyzati kzmy. A talmy szerinti gyyzatikzmy hatnyagkt egyrzt milrinont vagy amrinont mrztvalamely ciklikus GMP foszfodiztergl tartalmaz agyyszerkzn szokos vivnyagok mellett.

A talmy tgya cskentett mellhat ken pozit inotrophatgyyzati kzmy. A talmy szerinti gyyzatikzmy hatnyagkt egyrzt milrinont vagy amrinont mrztizoszorbid-mononitrot tartalmaz a gyyszerkzn szokosvivnyagok mellett.

1. Use in preparation of a medicament for treating congestive heart failure (CHF) in a human patient suffering therefrom of an aliquot of modified blood of the patient prepared by treating the aliquot of the patient's blood ex vivo with stressors comprising ultraviolet light and an oxidative environment. 2. Use according to claim 1 wherein the oxidative environment used in treating the blood aliquot comprises application of an oxidizing agent to the aliquot. 3. Use according to claim 2 wherein t...

D.N. 3686 The process which comprises reacting 4-picoline below about 30.degree.C. with at least three mole equivalents of an inorganic acid halide preferably phosphorus oxychloride per mole of 4-picoline and excess dimethylformamide reacting in solution the unisolated resulting N-¢3-dimethylamino-2- (4-pyridinyl)-2-propenylidene¢-N-methylmethaniminium salt (after adding the reaction mixture to cold water adjusting the pH to about 8.0 and filtering off the precipitated inorganic cationic salts) ...

Amrinone-N-glucuronide or pharmaceutically-acceptable acid-addition or cationic salt thereof useful as cardiotonic agent is prepared by reacting amrinone with glucuronic acid or cationic salt thereof. Cardiotonic composition and method for increasing cardiac contractility using said amrinone-N-glucuronide or salt as active component are disclosed.